Friberg Gregory R 4

What Happened
Gregory R. Friberg, EVP and Chief R&D Officer of BioMarin Pharmaceutical (BMRN), sold 6,326 shares in an open-market/private sale on February 26, 2026. The weighted-average sale price was $60.38 per share, generating gross proceeds of approximately $381,937. This was a sale (not a purchase), which is often routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date: 2026-02-26. Transaction type: Sale (code S).
• Amount sold: 6,326 shares. Weighted-average price: $60.38; price range reported $60.36–$60.51 (see footnote F1).
• Proceeds: ~ $381,937 (gross).
• Shares owned after the transaction: Not specified in the provided filing.
• Footnote: F1 clarifies the price shown is a weighted average; exact number of shares sold at each price is available upon request to the issuer, holders, or SEC staff.
• Filing timeliness: Report filed the same day (timely); no 10b5‑1 plan or tax-withholding note disclosed in the provided details.

Context
Sales by executives can be routine (portfolio diversification, tax planning, or liquidity needs) and do not necessarily indicate a change in company outlook. Because this filing shows a straightforward open-market sale with no accompanying purchase or option exercise, there’s no direct evidence here of added insider confidence.